“Bimekizumab Efficacy and Safety Through 3 Years in Patients With Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s762, https://doi.org/10.25251/g776yf41.